The National Pharmaceutical Council (NPC), a health policy research organization dedicated to the advancement of good evidence, science and medical innovation, has appointed Sharon Phares, PhD, MPH, as Chief Scientific Officer. Dr. Phares will replace Robert Dubois, MD, PhD, who is retiring from NPC at the end of February 2022.
 

Dr. Phares will direct NPC’s research strategy and oversee the organization’s research on policy issues, including demystifying pharmaceutical pricing perceptions, addressing challenges of health technology assessments, and examining underlying issues of patient access and affordability.
 
Prior to joining NPC, Dr. Phares was the Senior Vice President of Research at Pharmaceutical Strategies Group (PSG), an EPIC company, where she developed and managed all research efforts, transforming research objectives into study designs, analytic plans, and survey tools, and translating research findings into actionable information to support both internal and external clients. She also serves as an Adjunct Assistant Professor of Medicine at the Washington University School of Medicine in St. Louis.
 
“Dr. Phares’ background and experience in health policy research and vision for NPC’s future research make her the perfect person to lead our research team. I’m confident in what we will accomplish this year and beyond as the pharmaceutical industry continues to face challenges around policy and patient affordability while simultaneously delivering life-changing treatments like never before,” said NPC President and CEO John M. O’Brien, PharmD, MPH.